Fort Washington Investment Advisors Inc. OH Sells 539,918 Shares of Johnson & Johnson $JNJ

Key Points

• Fort Washington Investment Advisors cut its Johnson & Johnson position by 57.2%, selling 539,918 shares in the third quarter and retaining 404,591 shares valued at approximately $107.1 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson exceeded quarterly expectations with adjusted EPS of $2.59 and revenue of $25.40 billion, up 5.9% year over year, while maintaining 2026 adjusted EPS guidance of $11.05–$11.15.
• The company declared a $1.34 quarterly dividend, equivalent to $5.36 annually and a 2.1% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $274.35, although MedTech weakness and insider selling remain concerns.

Fort Washington Investment Advisors Inc. OH decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 57.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 404,591 shares of the company's stock after selling 539,918 shares during the period. Fort Washington Investment Advisors Inc. OH's holdings in Johnson & Johnson were worth $107,111,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. B.A. Schrock Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the third quarter valued at about $5,553,000. Nolet Wealth Management LLC grew its position in shares of Johnson & Johnson by 2.9% in the 3rd quarter. Nolet Wealth Management LLC now owns 2,655 shares of the company's stock worth $703,000 after buying an additional 74 shares during the last quarter. Howard Financial Services LTD. grew its position in shares of Johnson & Johnson by 10.1% in the 3rd quarter. Howard Financial Services LTD. now owns 7,789 shares of the company's stock worth $2,062,000 after buying an additional 717 shares during the last quarter. ZWJ Investment Counsel Inc. increased its stake in shares of Johnson & Johnson by 3.0% during the third quarter. ZWJ Investment Counsel Inc. now owns 231,462 shares of the company's stock valued at $61,277,000 after buying an additional 6,670 shares during the period. Finally, Mather Group LLC. increased its stake in shares of Johnson & Johnson by 21.3% during the third quarter. Mather Group LLC. now owns 81,293 shares of the company's stock valued at $21,522,000 after buying an additional 14,250 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $253.68 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a market cap of $611.35 billion, a P/E ratio of 38.44, a P/E/G ratio of 2.59 and a beta of 0.21. The business's 50 day moving average price is $265.73 and its 200-day moving average price is $249.57. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on JNJ shares. Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Sanford C. Bernstein set a $270.00 price target on shares of Johnson & Johnson in a report on Thursday. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 15th. Citigroup boosted their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a research report on Monday, October 5th. Finally, Guggenheim restated a "buy" rating and issued a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $274.35.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 87,569 shares of company stock valued at $23,064,544 over the last ninety days. Insiders own 0.16% of the company's stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share and revenue of $25.40 billion, exceeding consensus estimates. Revenue increased 5.9% year over year, led by 7.9% growth in Innovative Medicine. J&J Q3 2026 Earnings Call Transcript
• Positive Sentiment: Management raised its 2026 sales and earnings outlook, with guidance of approximately $11.05–$11.15 in adjusted EPS. Executives also highlighted pipeline products and MedTech innovation as potential sources of future growth. JNJ Q3 Earnings Call Highlights
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating, while RBC retained an “outperform” rating, indicating that analysts still see potential upside despite trimming their price targets. Technical analysts also identified support near $246. Morgan Stanley JNJ Price Target
• Neutral Sentiment: Johnson & Johnson plans an enterprise review on December 8 and is targeting a potential mid-2027 spinoff of its DePuy Synthes orthopedics business. These initiatives could clarify the company’s growth strategy but may also create execution and earnings-dilution concerns. J&J MedTech Orthopedics Spinoff
• Negative Sentiment: MedTech sales missed Wall Street expectations, with weakness attributed partly to China pricing pressure and European budget cuts. Investors viewed the device business as a key reason the stock fell sharply following earnings. Johnson & Johnson Stock Falls as MedTech Misses
• Negative Sentiment: Analysts lowered several price targets after the results, citing mixed pharmaceutical trends, acquisition costs, talc-related charges and potential 2027 dilution. The concerns are more significant because JNJ trades at a premium earnings multiple versus the broader market. Analysts Cut JNJ Forecasts

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.